Ace Therapeutics is an expert in the field of alcoholic liver disease. We aim to provide the most professional service to facilitate research advances in the development of drugs for alcoholic liver disease.
Alcoholic liver disease is the second most common cause of human death and has far-reaching implications for public health. Based on our dedicated research team and advanced research platform, we offer a comprehensive range of services to target drug development for alcoholic liver disease.
What Can We Do?
We offer a comprehensive research service for the different directions of drug development for alcoholic liver disease in order to facilitate progress in the field of drug development for alcoholic liver disease.
- Drug Development Targeting TNF Receptor Superfamily for Liver Disease
The TNF superfamily plays an important role in various immune and inflammatory response processes. We offer a comprehensive drug development service targeting the regulatory role of the TNF superfamily in the pathology of alcoholic liver disease.
- We will screen extensively for TNF-α inhibitors to inhibit the development of alcoholic hepatitis.
- For candidate small molecule inhibitors, we will further screen candidates that are highly specific and less prone to off-target toxicity.
- Based on the antibody development platform, we will develop custom monoclonal antibodies targeting the TNF superfamily for enhanced targeting.
- Drug Development Targeting Oxidative Stress for Liver Disease
The metabolism of alcohol is accompanied by the involvement of oxidative processes, and studies have identified many antioxidant genes as potent targets in alcoholic liver disease. Therefore, we offer targeted drug development services for the oxidative stress process in alcoholic liver disease.
- We will screen a wide range of drug candidates against targets such as GST, SOD, NQO1, and HO-1 to treat liver disease by enhancing antioxidant activity.
- We will screen activators against antioxidant genes such as Nrf-2 and NF-κB to enhance the antioxidant capacity of the body.
- Drug Development Targeting Microbiome in Liver Disease
In alcoholic liver disease, the microbiome can contribute to processes such as metabolic dysfunction, oxidative stress, inflammation, and hepatocellular damage. Therefore, targeting the microbiome to develop drugs for liver disease can modulate multiple pathological processes and is a valid target for drug development.
- We will modulate the composition of the microbiome by screening for phages that specifically adsorb to target bacteria for the purpose of lysing them.
- We will screen for probiotics through a combination of microbiomics and metabolomics studies. These probiotics will then be developed into active drugs to modulate the composition of the microbiome.
- We will screen for effective antibiotics to inhibit the proliferation of harmful bacteria and thereby modulate the composition of the microbiome.
Ace Therapeutics has an elite team in the field of alcoholic liver disease. Our scientists will develop an exclusive service plan based on your research. If you would like to learn more about our services, please feel free to contact us.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
